FDA still isn't really throwing its weight behind Covid-19 vaccine boosters, Moderna's adcomm briefing docs show
As the two top vaccine experts at the FDA retired in protest over the way the Covid-19 booster shot process has transpired, the agency on Tuesday released its findings on the Moderna vaccine booster data ahead of an adcomm meeting later this week, offering the same tentative support that the Pfizer booster received.
While authorization of the Moderna booster is basically a done deal, as it was with Pfizer’s before the process began (since the post-authorization CDC advisory committee has already been scheduled), the FDA’s briefing documents make clear that the agency doesn’t find the data on booster efficacy to be particularly persuasive.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 120,500+ biopharma pros reading Endpoints daily — and it's free.